Hyloris Pharmaceuticals has reported a 44% increase in its revenues on the back of increased royalties and licensing income while doubling down on its R&D expenses and portfolio expansion in its 2023 annual results report.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?